ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0263

Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease

Taylor Koenig1, David Fell1, Danny Mammo1, Chao Zhang2, Sunil Srivastava1, Careen Lowder1, Sumit Sharma1 and Rula Hajj-Ali1, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland, OH

Meeting: ACR Convergence 2023

Keywords: Eye Disorders, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Noninfectious inflammatory eye disease (NIIED) is a sight-threatening condition with two-thirds of patients incurring prolonged vision loss due to uncontrolled ocular inflammation. Non-glucocorticoid systemic therapy (NGST) effectively induces and maintains remission in NIIED. However, minimal research exists on the risk factors for requiring long-term NGST for NIIED control or for NIIED relapse after discontinuation of NGST.

Methods: We performed a retrospective chart review of NIIED patients who were evaluated by the Cleveland Clinic Ophthalmology and Rheumatology departments and initiated NGST between January 1, 2014 through December 31, 2018, and had at least 4 years of follow-up prior to December 31, 2022. If treatment was dictated by systemic disease, patients were excluded. Data were extracted from the electronic medical record. The association between patient characteristics and the groups were analyzed through univariate logistic regression.

Results: 94 NIIED patients were included in the study. 78 patients (83.0%) were maintained on NGST throughout the study period, designated as long-term NGST. 16 patients (17.0%) had NGST discontinued due to inactive NIIED, denoted as short-term NGST. NIIED location was significantly different between the two groups (Table 1). Patients with intermediate, posterior, or pan uveitis were more likely to require long-term NGST compared to patients with anterior uveitis (Table 2). Age, sex, race, presence of systemic disease, and treatment with biologic or nonbiologic medication were not significantly different between the groups. However, data trends showed that patients with white race were more likely to require long-term NGST than non-white race; earlier initiation of NGST was more represented in the short-term NGST group which may imply that earlier initiation of NGST confers a greater likelihood of discontinuing NGST due to inactive NIIED. Within the short-term NGST group, 11 patients (68.8%) had inactive NIIED for ≥ 1 year, designated as sustained remission, and 5 patients (31.3%) had relapse of active NIIED < 1 year, designated as intermediate group. NIIED patients with sustained remission tended to be diagnosed at an older age and had earlier initiation of NGST than the intermediate group (Table 3).

Conclusion: This study provides insight into the risk factors for requiring long-term NGST and sustained remission for patients with NIIED. Our results demonstrate that NIIED location of intermediate, posterior, or pan uveitis is a risk factor for requiring long-term NGST. Older age and earlier initiation NGST may be associated with sustained remission of NIIED.

Supporting image 1

Descriptive comparison of risk factors between Short-Term vs Long-Term NGST groups for NIIED patients. NIIED location was significantly different between the two groups. Patients in the short-term NGST group had earlier initiation of NGST than patients in the long-term NGST group.

Supporting image 2

Univariate logistic regression results of risk factors between short-term NGST and long-term NGST groups. Patients with intermediate, posterior, or pan uveitis were more likely to be in the long-term NGST group than patients with anterior uveitis.

Supporting image 3

Descriptive comparison of risk factors between patients in the Intermediate v Sustained Remission Groups. The sustained remission group was diagnosed at an older age and had earlier initiation of NGST than patients in the intermediate group.


Disclosures: T. Koenig: None; D. Fell: None; D. Mammo: Alimera Sciences, 1; C. Zhang: None; S. Srivastava: Abbvie, 2, Allergan, 12, Financial Support, Bausch and Lomb, 2, Eyepoint, 2, 12, Financial Support, Eyevensys, 2, Novartis, 2, Regeneron, 2, 12, Financial Support, Santen, 12, Financial Support, Zeiss, 2; C. Lowder: None; S. Sharma: AbbVie/Abbott, 2, Alimera, 2, Allergan, 2, Apellis, 2, Bausch and Lomb, 2, Clearside, 2, Eyepoint, 2, Genentech, 2, 5, Gilead, 5, Regeneron, 2, RegenxBio, 2, Roche, 2, 5; R. Hajj-Ali: Amgen, 2, GlaxoSmithKlein(GSK), 2, uptodate, 9.

To cite this abstract in AMA style:

Koenig T, Fell D, Mammo D, Zhang C, Srivastava S, Lowder C, Sharma S, Hajj-Ali R. Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/patient-disease-and-treatment-factors-in-remission-of-inflammatory-eye-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-disease-and-treatment-factors-in-remission-of-inflammatory-eye-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology